OncoAssign
Unlocking tumour diversity for enhanced treatment prediction
- Stage Prototype Ready
- Industry Oncology
- Location Nashville, TN, USA
- Currency USD
- Founded August 2023
- Employees 3
- Incorporation Type C-corp
Company Summary
At OncoAssign, we’re developing a one-stop solution for bowel cancer treatment. Harnessing the power of tumour heterogeneity, we’ve developed our proprietary RNA based stratification technique to create a treatment pipeline covering all parts of a patient’s treatment journey: Prognostication, Treatment Prediction, and Response Monitoring.
Team
-
Ashwin completed his PhD (DPhil) in Oncology at the University of Oxford. He has over 8 years of scientific experience in Oncology, being a post-doctoral fellow both at the Institute of Cancer Research and at the University of Oxford. He is also an entrepreneurship fellow at the Saïd Business School, University of Oxford. He has previously founded an Oncology start-up in Oxford.
-
CEOSushanth brings in over a decade of management experience. He serves as the Global Director of Business Development at Ricardo plc – an international engineering business. Since 2020 he has been building a business focused on developing safety critical systems for next generation electric and hydrogen powered aircraft. He holds multiple engineering degrees and an Executive MBA from London Business School.
-
Anguraj SadanandamCSOHe is the Director of the Centre for Global Oncology, and Head of the Stratified and Precision Medicine Team at the Institute of Cancer Research, London. He has led the research work to define molecular classifications of pancreatic, colorectal, gastroesophageal, and breast cancers associated with prognosis and personalized therapies, and contributes to various consortia and clinical studies.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.